Our work with King's College London (KCL) School of Biomedical Engineering & Imaging Sciences to design machine learning approaches to evaluate imaging of patients with rheumatoid arthritis using maraciclatide is continuing to make good progress. Congratulations to our KCL colleagues Andrew Reader, Gary Cook and Robert Cobb who have had a paper on their ongoing research titled: “Improved Classification Learning from Highly Imbalanced Multi-Label Datasets of Inflamed Joints in ⁹⁹ᵐTc-Maraciclatide Imaging of Arthritic Patients by Natural Image and Diffusion Model Augmentation” accepted for presentation at the International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI Society) later this year. Maraciclatide is in development to diagnose and detect inflammation in patients with inflammatory arthritis and endometriosis. The development of AI tools could enhance the potential of maraciclatide as a new imaging marker. See more details here: https://lnkd.in/eUpdj33T Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities. #molecularimaging #medicalimaging #AI #machinelearning #rheumatoidarthritis #endometriosis #nuclearmedicine #precisionmedicine #MICCAI2024
Serac Healthcare
Biotechnology Research
a clinical radiopharmaceutical company developing innovative molecular imaging technologies.
About us
Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.
- Website
-
www.serachealthcare.com
External link for Serac Healthcare
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2017
- Specialties
- nuclear medicine, molecular imaging, inflammatory arthritis, endometriosis, and radiopharmaceutical
Locations
-
Primary
London, GB
Employees at Serac Healthcare
Updates
-
We very much welcome the recent NCEPOD report ‘A Long and Painful Road’ which includes new research on the quality of care provided to endometriosis patients and recommends improvements including exploring “the use of imaging modalities in the diagnosis of endometriosis.” Our innovative imaging marker - maraciclatide - is currently being investigated as a tool for detecting, in particular, superficial peritoneal endometriosis which is currently only possible with laparoscopy. #endometriosis #womenshealth #molecularimaging #diagnosticimaging #medicalimaging #precisionmedicine #nuclearmedicine
New report out today on #endometriosis https://lnkd.in/df8bT95q
-
-
We are excited to report that an abstract on preliminary data from our DETECT imaging study has been accepted as a Top Rated Oral Presentation at the annual congress of the European Association of Nuclear Medicine (EANM) taking place from 18-23 October 2024 in Hamburg, Germany. The DETECT study is evaluating the potential of maraciclatide to visualise endometriosis, and specifically superficial peritoneal endometriosis, which could have a significant impact on the lives of millions of women suffering with the disease. The study is ongoing and the presentation will include the latest findings and insights into the detection of disease subtypes. Many thanks to authors Munir Ghesani MD, FACNM, FACR, FSNMMI Jon Barnett Tatjana Gibbons Druin Burch; S Cade and R Graham (Royal United Hospitals Bath NHS Foundation Trust); N Patel (John Radcliffe Hospital, Oxford); Krina Zondervan and C Becker (Nuffield Dept of Women's & Reproductive Health, University of Oxford and EndoCaRe Oxford 🎗️ ). Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities. #endometriosis #womenshealth #molecularimaging #diagnosticimaging #medicalimaging #precisionmedicine #nuclearmedicine
-
-
We are excited to report major news this week for the development of ⁹⁹ᵐTc-maraciclatide as an imaging agent for endometriosis: the US Food & Drug Administration (FDA) has granted fast track designation to maraciclatide "for the visualisation and diagnosis of superficial peritoneal endometriosis in women 16 years of age or older". Fast track is a process designed to facilitate the development and expedite the review of drugs to treat (or in our case, diagnose) serious conditions and fill an unmet medical need so that patients can benefit sooner. Superficial peritoneal endometriosis (SPE) is the earliest and most common form of endometriosis, comprising approximately 80% of all diagnoses. SPE is not well visualised with current non-invasive imaging tools (ultrasound and MRI) and definitive diagnosis requires laparoscopy. In data previously reported from the DETECT study being run by our colleagues at the Nuffield Dept of Women's & Reproductive Health, University of Oxford, maraciclatide correctly identified superficial peritoneal endometriosis in those who went on to have this early-stage endometriosis confirmed by laparoscopy. Please see full details here: https://lnkd.in/eQM3nCKm Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities. #FDAFastTrack #endometriosis #womenshealth #molecularimaging #diagnosticimaging #medicalimaging #precisionmedicine #nuclearmedicine EndoCaRe Oxford 🎗️ Spectrum Dynamics Medical Hermes Medical Solutions Krina Zondervan Tatjana Gibbons
-
-
Great to see our DETECT study covered earlier this month in PharmaTimes here: https://lnkd.in/dpUrYGnV #womenshealth #molecularimaging #medicalimaging #endometriosis #precisionmedicine #nuclearmedicine Nuffield Dept of Women's & Reproductive Health, University of Oxford Tatjana Gibbons Krina Zondervan
-
Continuing positive results from the DETECT study comparing the imaging of superficial peritoneal endometriosis by ⁹⁹ᵐTc-maraciclatide with laparoscopic surgery are being presented today in a poster by one of the investigators, Dr Tatjana Gibbons from the Nuffield Dept of Women's & Reproductive Health, University of Oxford. The poster will be on display at the 7th European Endometriosis Congress taking place in Bucharest from 6-8 June. For full details, please see the press release here https://lnkd.in/eC42HGhV #endometriosis #womenshealth #molecularimaging #diagnosticimaging #medicalimaging #precisionmedicine #nuclearmedicine #EEC2024 European Endometriosis League Spectrum Dynamics Medical Hermes Medical Solutions Krina Zondervan Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.
-
-
Jon Barnett, Programme Director for maraciclatide, our molecular imaging agent in development for endometriosis and inflammatory arthritis is heading off to Bucharest this week to attend the 7th European Endometriosis Congress (EEC) from 6-8 June. He will be joining Dr Tatjana Gibbons from the Nuffield Dept of Women's & Reproductive Health, University of Oxford who is a key member of the Oxford University team running our DETECT study evaluating maraciclatide as a non-invasive test for endometriosis. Dr Gibbons is also the author of a poster which will be displayed at the EEC highlighting the latest interim findings from the ongoing DETECT study. #medicalimaging #diagnosticimaging #womenshealth #endometriosis #inflammatoryarthritis #precisionmedicine #nuclearmedicine #molecularimaging #EEC2024 Spectrum Dynamics Medical European Endometriosis League
-
-
David Hail and Paul Cload are off to Toronto next week to attend the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting from 8-11 June. They are looking forward to meeting up with old friends and making new connections. Please do get in touch if you’d like to get up to speed on our molecular imaging agent, maraciclatide, in development for endometriosis and inflammatory arthritis. #medicalimaging #diagnosticimaging #womenshealth #endometriosis #inflammatoryarthritis #precisionmedicine #nuclearmedicine #molecularimaging
-
-
Congratulations to Krina Zondervan on this well-deserved recognition for her research work for the benefit of women’s health. Professor Zondervan is one of the principal investigators on our DETECT trial investigating maraciclatide as a molecular imaging diagnostic tool for endometriosis. We are most fortunate to benefit from the expertise of Professor Zondervan and her colleagues at the Nuffield Dept of Women's & Reproductive Health, University of Oxford on this study. #endometriosis #womenshealth #molecularimaging #medicalimaging #diagnosticimaging
We are thrilled to announce that The Academy of Medical Sciences has elected eight distinguished biomedical and health scientists from the University of Oxford to its prestigious fellowship for the year 2024. Among these esteemed individuals is our very own Head of Department, Krina Zondervan, recognised for her outstanding contributions to women’s health. For further information click here: https://lnkd.in/eGwN3-za Congratulations to Professor Zondervan and all the new Fellows on this well-deserved honour! 🎉 #MedicalSciences #WomenInHealth #OxfordUniversity #AcademyFellows2024 #WomenOfScience #reproductivehealth #Endometriosis
Krina Zondervan among eight Oxford Researchers elected as Fellows of the Academy of Medical Sciences
wrh.ox.ac.uk
-
Many thanks to Christiane Hagel, Oxford FemTech Society President for the invitation to participate in the inaugural FemTech Soc event last Friday at Green Templeton College, Oxford University, which set out to explore the benefits of applying technology to address longstanding gaps in women’s health. Our molecular imaging tool, maraciclatide which is in development to diagnose endometriosis, was one of the potential solutions highlighted to improve women’s health by improving the diagnosis of this condition which currently affects 1 in 10 women and takes an average of 9 years to diagnose. It was great to share the platform with our colleagues Professor Christian Becker and Dr Tatjana Gibbons from the Nuffield Dept of Women's & Reproductive Health, University of Oxford who explained the current limitations to diagnosing endometriosis and presented data from our ongoing DETECT study (see image of Dr Gibbons presenting below). Druin Burch, our CSO, and Jon Barnett, Programme Director, also very much enjoyed stimulating discussions with others with a keen interest in this space. #femtechforward2023 #oxfordfemtech #endometriosis #molecularimaging #diagnosticimaging #precisionmedicine #womenshealth
-